Supplemental material
OncoImmunology
Volume 13, 2024 - Issue 1
Open access
1,480
Views
0
CrossRef citations to date
0
Altmetric
Original research
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma
Morten Nielsena National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
https://orcid.org/0000-0002-1250-4885View further author information
Tine Monberga National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
https://orcid.org/0000-0002-7217-2974View further author information
Vibeke Sundvoldb Lytix Biopharma, Oslo, Norway
https://orcid.org/0000-0002-1819-3889View further author information
Benedetta Albieria National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
https://orcid.org/0009-0008-3202-5452View further author information
Dorrit Hovgaardc Department of Orthopedic Surgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkView further author information
, Michael Mørk Petersenc Department of Orthopedic Surgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
https://orcid.org/0000-0002-2324-6420View further author information
Anders Krarup-Hansend Department of Oncology, Herlev and Gentofte Hospital, Herlev, DenmarkView further author information
, Özcan Meta National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark;e Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
https://orcid.org/0000-0002-3256-7592View further author information
Ketil Camiliob Lytix Biopharma, Oslo, NorwayView further author information
, Trevor Clancyf NEC Oncoimmunity AS, Oslo, Norway
https://orcid.org/0000-0001-9896-0613View further author information
Richard Stratfordf NEC Oncoimmunity AS, Oslo, NorwayView further author information
, Baldur Sveinbjornssonb Lytix Biopharma, Oslo, Norway
https://orcid.org/0000-0002-5499-9345View further author information
Øystein Rekdalb Lytix Biopharma, Oslo, Norway
https://orcid.org/0000-0001-5563-6709View further author information
Niels Junkerd Department of Oncology, Herlev and Gentofte Hospital, Herlev, DenmarkView further author information
& Inge Marie Svanea National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkCorrespondence[email protected]
https://orcid.org/0000-0002-9451-6037View further author information
Article: 2290900
|
Received 15 Sep 2023, Accepted 30 Nov 2023, Published online: 07 Dec 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.